New York City, NY -- (SBWIRE) -- 12/23/2013 -- StockMarketIntel.com issues a special report on the following stocks: Frontline Ltd. (NYSE:FRO), Mitsubishi Estate Co Ltd (ADR) (OTCMKTS:MITEY), Applied Materials, Inc. (NASDAQ:AMAT), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).
Frontline Ltd. (NYSE:FRO) stock not showed any percentage change and stayed at 0.00%and closed at the price of $3.58 after opening at $3.57. The stock traded during its last trading session with the total volume of 2.02 million shares, as compared to its average volume of 1.57 million shares. Frontline Ltd., through its subsidiaries, engages in the ownership and operation of oil tankers.
How Should Investors Trade FRO Now? Don’t Miss out a Special Trend Analysis
Mitsubishi Estate Co Ltd (ADR) (OTCMKTS:MITEY) remained among the day bullish 1.86% and traded with volume of 54,174.00 shares in the last session, as compared to average volume of 40,232.00 shares. In comparison with 52 week range of $21.75 - $33.45, it faced lowest price of $28.78 during the last trading session whereas its day highest price was $29.08. The company’s total market capitalization is $39.70 billion. Mitsubishi Estate Co., Ltd. is engaged in the real estate activities in Japan and internationally.
Will MITEY Continue To Move Higher? Find out via this report
Applied Materials, Inc. (NASDAQ:AMAT) showed 17.97 million shares in volume during the last trading session, while the average trading volume remained 11.46 million shares. The stock kicked off its trading session at $16.83 and closed at $17.19 after rallied 1.84%. Applied Materials, Inc. provides manufacturing equipment, services, and software to the semiconductor, flat panel display, solar photovoltaic (PV), and related industries worldwide.
Why Should Investors Buy AMAT After The Recent Gain? Just Go Here and Find Out
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock traded during its last trading session with the total traded volume of 6.06 million shares versus its average volume of 5.65 million shares. The company opened its trade at the price of $5.63 and its closing price was $5.57 after fell -0.54% for the day. Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
Has ARNA Found The Bottom and Ready To Move Up? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)